DXCM DEXCOM INC

Nasdaq dexcom.com


$ 65.89 $ 0.00 (0 %)    

Friday, 17-Oct-2025 07:09:23 EDT
QQQ $ 595.56 $ 0.00 (0 %)
DIA $ 458.22 $ 0.00 (0 %)
SPY $ 657.18 $ 0.00 (0 %)
TLT $ 91.38 $ 0.00 (0 %)
GLD $ 398.34 $ 0.00 (0 %)
$ 66.33
$ 66.00
$ 65.16 x 15
$ 65.91 x 40
-- - --
$ 57.52 - $ 93.25
3,956,649
na
26.01B
$ 1.35
$ 45.51
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-30-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 02-14-2025 12-31-2024 10-K
4 10-24-2024 09-30-2024 10-Q
5 07-25-2024 06-30-2024 10-Q
6 04-25-2024 03-31-2024 10-Q
7 02-08-2024 12-31-2023 10-K
8 10-26-2023 09-30-2023 10-Q
9 07-27-2023 06-30-2023 10-Q
10 04-27-2023 03-31-2023 10-Q
11 02-09-2023 12-31-2022 10-K
12 10-27-2022 09-30-2022 10-Q
13 07-28-2022 06-30-2022 10-Q
14 04-28-2022 03-31-2022 10-Q
15 02-14-2022 12-31-2021 10-K
16 10-28-2021 09-30-2021 10-Q
17 07-29-2021 06-30-2021 10-Q
18 04-29-2021 03-31-2021 10-Q
19 02-11-2021 12-31-2020 10-K
20 10-27-2020 09-30-2020 10-Q
21 07-28-2020 06-30-2020 10-Q
22 04-28-2020 03-31-2020 10-Q
23 02-13-2020 12-31-2019 10-K
24 11-06-2019 09-30-2019 10-Q
25 07-31-2019 06-30-2019 10-Q
26 05-01-2019 03-31-2019 10-Q
27 02-21-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-01-2018 06-30-2018 10-Q
30 05-02-2018 03-31-2018 10-Q
31 02-27-2018 12-31-2017 10-K
32 11-01-2017 09-30-2017 10-Q
33 08-01-2017 06-30-2017 10-Q
34 05-02-2017 03-31-2017 10-Q
35 02-28-2017 12-31-2016 10-K
36 11-01-2016 09-30-2016 10-Q
37 08-02-2016 06-30-2016 10-Q
38 04-27-2016 03-31-2016 10-Q
39 02-23-2016 12-31-2015 10-K
40 11-04-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 truist-securities-maintains-buy-on-dexcom-lowers-price-target-to-94

Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $102 t...

 citigroup-maintains-buy-on-dexcom-lowers-price-target-to-85

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $105 to $85.

 goldman-sachs-maintains-buy-on-dexcom-lowers-price-target-to-89

Goldman Sachs analyst Kate McShane maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $104 to $89.

 health-care-stocks-rally-nike-beats-the-street-whats-moving-markets-wednesday

Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps m...

 canaccord-genuity-maintains-buy-on-dexcom-maintains-106-price-target

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ: DXCM) with a Buy and maintains $106 price target.

 forecasting-the-future-10-analyst-projections-for-dexcom

10 analysts have expressed a variety of opinions on DexCom (NASDAQ: DXCM) over the past quarter, offering a diverse set of opin...

 baird-maintains-outperform-on-dexcom-lowers-price-target-to-90

Baird analyst Jeff Johnson maintains DexCom (NASDAQ: DXCM) with a Outperform and lowers the price target from $112 to $90.

 darden-humana-and-rocket-lab-are-among-top-10-large-cap-losers-last-week-sep-15--sep-19-are-the-others-in-your-portfolio

Darden, Humana, Rocket Lab, and FactSet led last week's large-cap losers, with declines driven by weak earnings, guidance, ...

 wall-street-extends-gains-apple-jumps-to-highest-since-february-whats-moving-markets-friday

Wall Street kept driving equity valuations higher on Friday, extending the momentum from Thursday when all major U.S. benchmark...

 short-report-alleges-dexcom-sold-faulty-g7-device-cited-by-fda

Dexcom faces mounting scrutiny over G7 safety concerns, FDA violations, financial practices, and growing competition from Abbot...

 fda-issues-update-to-continuous-glucose-monitor-apps-correction-dexcom-inc-issues-correction-for-g7-apps-and-one-apps-due-to-a-software-design-error-that-does-not-alert-users-of-unexpected-sensor-failure

https://www.fda.gov/medical-devices/medical-device-recalls/continuous-glucose-monitor-apps-correction-dexcom-inc-issues-correct...

 continuous-glucose-monitor-apps-correction-dexcom-inc-issues-correction-for-g7-apps-and-one-apps-due-to-a-software-design-error-that-does-not-alert-users-of-unexpected-sensor-failure---fda

https://www.fda.gov/medical-devices/medical-device-recalls/continuous-glucose-monitor-apps-correction-dexcom-inc-issues-correct...

 why-traders-fear-september-10-sp-500-stocks-to-watch-as-weak-seasonality-kicks-in

September has a long-standing bearish reputation for U.S. stocks. Here's what history tells us—and the S&P 500 stocks t...

 marvell-technology-ebay-and-dexcom-are-among-top-10-large-cap-losers-last-week-august-25-august-29-are-the-others-in-your-portfolio

Marvell, Hormel, and Keurig Dr Pepper led weekly large-cap losers on weak guidance and analyst downgrades.

 pe-ratio-insights-for-dexcom
P/E Ratio Insights for DexCom
08/29/2025 15:00:31

 nvidia-rises-wall-street-pauses-as-oil-prices-jump-to-65-whats-moving-markets-monday

Nvidia Corp. (NASDAQ:NVDA) is up 2% in midday trading Monday, moving within striking distance of its all-time high—now less tha...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION